Financings in Brief: Biopsys
This article was originally published in The Gray Sheet
Executive Summary
Biopsys: Expects net proceeds of $28.5 mil. from initial public offering of 2.25 mil. shares. The Irvine, California-based company filed a registration statement with SEC March 19 for the offering, shares in which are expected to be priced between $13 and $15 each. Robertson, Stephens & Company and Piper Jaffray are underwriting and will retain an option to buy an additional 337,500 shares to cover over-allotments, according to the prospectus. Proceeds from the offering are tabbed to fund an expansion of sales and marketing activities, an increase of manufacturing capabilities for the company's Mammotome biopsy system and MicroMark Clip, and to fund research and development activities, the firm says.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.